title: Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.
abstract: OBJECTIVE
  The authors assessed the experimental noradrenergic compound tomoxetine as an alternative treatment for adult attention deficit hyperactivity disorder (ADHD).
  
  
  METHODS
  They conducted a double-blind, placebo-controlled, crossover study of tomoxetine in 22 adults with well-characterized ADHD.
  
  
  RESULTS
  Treatment with tomoxetine at an average oral dose of 76 mg/day was well tolerated. Drug-specific improvement in ADHD symptom was highly significant overall and sufficiently robust to be detectable in a parallel-groups comparison restricted to the first 3 weeks of the protocol. Eleven of 21 patients showed improvement after receiving tomoxetine, compared with only two of 21 patients who improved after receiving placebo. Significant tomoxetine-associated improvement was noted on neuropsychological measures of inhibitory capacity from Stroop tests.
  
  
  CONCLUSIONS
  This preliminary study showed that tomoxetine was effective in treating adult ADHD and was well tolerated. These promising results provide support for further studies of tomoxetine over an extended period of treatment.
authors.affiliation: Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA.
authors.forename: T
authors.initials: T
authors.lastname: Spencer
authors.forename: J
authors.initials: J
authors.lastname: Biederman
authors.forename: T
authors.initials: T
authors.lastname: Wilens
authors.forename: J
authors.initials: J
authors.lastname: Prince
authors.forename: M
authors.initials: M
authors.lastname: Hatch
authors.forename: J
authors.initials: J
authors.lastname: Jones
authors.forename: M
authors.initials: M
authors.lastname: Harding
authors.forename: S V
authors.initials: SV
authors.lastname: Faraone
authors.forename: L
authors.initials: L
authors.lastname: Seidman
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011437:Propylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D010919:Placebos; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride